news
First implantable pump kills brain cancer using chemo
The first implantable pump system bypassed the blood-brain barrier to deliver chemotherapy to brain cancer patients in a Phase I study.
List view / Grid view
Glioblastoma (GBM)
news
ITM licenses targeted radionuclide therapy candidate
The targeted radionuclide therapy for glioblastoma is administered into a tumour cavity via a reservoir post-surgery and standard post-operative therapy.
news
Immunotherapy shows benefits for hospitalised COVID-19 patients
Apogenix’s asunercept demonstrates efficacy in Phase II trial for the treatment of hospitalised COVID-19 patients.
article
Oncolytic viruses: past and present
It is difficult to treat cancer effectively without causing adverse side effects. In this article, Dr Li, Clinical Assistant Professor at the State University of New York and Board Director of ExonanoRNA, describes how an old strategy that never got off the ground has finally been leveraged to deliver safe,…
article
Achieving sustainable innovation with value-added medicines
The COVID-19 pandemic spotlighted drug repurposing as a key strategy to support traditional novel chemical entity development; yet repurposing is just one example of how off-patent molecules can be further developed to provide patients with more treatment options. Here, Arun Narayan, Chairman of the Value Added Medicines Sector Group at…
news
Cancer vaccine shows promise in glioblastoma trial
Personalised cancer vaccine increases progression free survival by approximately 50 percent in patients with newly diagnosed glioblastoma.
news
Novel nanocarrier enables targeted treatment of gliomas in vivo
The new nanoparticle formulation enabled researchers to selectively target glioma cells with Dp44mT, a potent chelator and promising anti-cancer therapeutic, for the first time.
news
Pelareorep-based combination therapy improves glioblastoma patient survival
In a Phase Ib trial, pelareorep with GM-CSF, chemoradiotherapy and temozolomide increased progression-free survival by an average of eight months.
article
A novel cannabinoid formulation for glioblastoma treatment
Earlier this year, MGC Pharmaceuticals, in collaboration with the Slovenian National Institute of Biology (NIB) and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia, announced successful research results for their novel cannabinoid formulation, which has been developed for the treatment of glioblastoma. This article highlights the key…
news
AI uses patient data to administer less toxic treatments
The researchers found that doses were often missed, with some treatments being scheduled twice a year instead of monthly...
news
Ibrutinib may benefit glioblastoma patients
An FDA-approved drug for lymphoma and leukaemia may also help treat the most common - and deadliest type of brain tumour...
news
Drug-delivering nanoparticles could help fight brain cancer
Nanoparticles carrying two drugs can cross the blood-brain barrier and shrink glioblastoma tumours...
news
Combination chemotherapy may significantly improve treatment for glioblastoma
Addition of hydroxyurea to current chemotherapy significantly improved survival in animal models of glioblastoma...
news
Zika virus shown to kill brain cancer stem cells
Research published in The Journal of Experimental Medicine suggests potential treatment for glioblastoma
news
First patient treated in Phase I VXM01 glioblastoma trial
Vaximm's VXM01 is an oral T-cell immunotherapy that targets the tumour-specific vasculature and certain immune-suppressive cells...
